MetaStat Inc. | Income Statement

Fiscal year is March-February. All values USD Thousands.
2014
2015
2016
2017
2018
Sales/Revenue
-
-
-
-
23.30
Cost of Goods Sold (COGS) incl. D&A
21.80
61.90
96.20
96.00
-
Gross Income
21.80
61.90
96.20
96.00
-
SG&A Expense
4,329.40
4,729.20
4,682.80
3,252.00
3,484.80
EBIT
4,351.20
4,791.10
4,779.00
3,348.00
3,550.50
Unusual Expense
32.90
118.30
300.50
1,580.30
488.10
Non Operating Income/Expense
-
66.50
141.60
111.50
0.60
Interest Expense
981.20
3,019.60
317.20
1,062.40
119.30
Pretax Income
5,365.20
7,995.50
4,654.20
2,941.60
3,181.00
Consolidated Net Income
5,365.20
7,995.50
4,654.20
2,941.60
3,181.00
Net Income
5,365.20
7,995.50
4,654.20
2,941.60
3,181.00
Net Income After Extraordinaries
5,365.20
7,995.50
4,654.20
2,941.60
3,181.00
Net Income Available to Common
5,365.20
8,237.50
5,988.70
6,217.60
3,310.10
EPS (Basic)
3.80
4.96
3.30
2.10
0.61
Basic Shares Outstanding
1,411.30
1,661.90
1,816.10
2,965.90
5,425.30
EPS (Diluted)
3.80
4.96
3.30
2.10
0.61
Diluted Shares Outstanding
1,411.30
1,661.90
1,816.10
2,965.90
5,425.30
EBITDA
4,329.40
4,729.20
4,682.80
3,252.00
3,461.50
Non-Operating Interest Income
0.10
-
-
-
-
Preferred Dividends
-
242.10
1,334.50
3,276.00
129.10

About MetaStat

View Profile
Address
27 Drydock Avenue
Boston Massachusetts 02210
United States
Employees -
Website http://www.metastat.com
Updated 07/08/2019
MetaStat, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes MetaSite Breast and MenaCalc platforms. The MetaSite Breast test measures the process of systemic metastasis and is intended for early stage breast cancer patients.